Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1356
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1355 to $1356.
Stocks · News reference
argenx shares are trading lower after the company announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous after the Independent Data Monitoring Committee concluded it is unable to meet its primary endpoint.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Maintains Outperform on argenx, Lowers Price Target to $1038
Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1100 to $1038.
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
argenx announced positive phase II results for FB102, an investigational therapy for celiac disease, meeting its primary endpoint with significant improvements in intestinal tissue measures versus placebo and no new safety signals. The company plans to advance FB102 into late-stage development and evaluate it for other autoimmune conditions. However, the stock declined nearly 12% following a separate announcement that argenx discontinued its phase III UNITY study for Vyvgart Hytrulo in Sjögren's disease.
Evercore ISI Group Maintains Outperform on argenx, Lowers Price Target to $1078
Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1175 to $1078.